Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 6/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL4140222 | 0.88 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL4154828 | 0.88 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL988740 | 0.88 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL454436 | 0.88 | FDPS (0.34) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL28436619 | 0.85 | FDPS (0.33) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL28492200 | 0.82 | TSHR (0.30) | TSHRNAPRTTDP1 | |
| Pyrimidine SCHEMBL27549056 | 0.82 | FDPS (0.32) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL27549055 | 0.82 | FDPS (0.32) | FDPSBTN3A1PDE3ATSHRNAPRT | |
| Pyrimidine SCHEMBL27748802 | 0.80 | FDPS (0.31) | FDPSBTN3A1PDE3A | |
| Foscarnet SCHEMBL15510548 | 0.78 | FDPS (0.33) | FDPSTSHRNAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 812 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101998988-A | Cytochrome P450 genes conferring herbicide resistance | SYNGENTA PARTICIPATIONS AG | 2011-03-30 | — | — | CN | claimed |
| CN-115799637-A | Electrolyte and battery comprising same | 珠海冠宇电池股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | BANK OF AMERICA, N.A. | 2022-09-01 | — | — | US | disclosed |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3926046-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | Sirna Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3354656-B1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) | SIRNA THERAPEUTICS INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3372684-B1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | SIRNA THERAPEUTICS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10584335-B2 | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | SIRNA THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| WO-2003070895-A2 | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) | RIBOZYME PHARMACEUTICALS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| WO-2003070912-A2 | RNA INTERFERENCE MEDIATED INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-31 | — | — | US | disclosed |
| CN-1349984-A | 2-pirimioxybenzyl substituted pyridyl amine derivative | ZHEJIANG PROV CHEMICAL ENGINEE (CN) | 2002-05-22 | — | — | CN | disclosed |
| CN-1348690-A | 2-pyrimioxybenzyl substituted phenyl amine derivatives | ZHEJIANG PROV INST OF CHEMICAL (CN) | 2002-05-15 | — | — | CN | disclosed |
| CN-1347876-A | 2-pyrimidyloxybenzyl substituted naphthyl amine derivative and its synthesis and use | SHANGHAI INST ORGANIC CHEM (CN) | 2002-05-08 | — | — | CN | disclosed |
| EP-1019429-A1 | ANTISENSE AND ANTIGENE THERAPEUTICS WITH IMPROVED BINDING PROPERTIES AND METHODS FOR THEIR USE | Somagenics Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999009045-A9 | ANTISENSE AND ANTIGENE THERAPEUTICS WITH IMPROVED BINDING PROPERTIES AND METHODS FOR THEIR USE | SOMAGENICS INC (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1999009045-A1 | ANTISENSE AND ANTIGENE THERAPEUTICS WITH IMPROVED BINDING PROPERTIES AND METHODS FOR THEIR USE | SOMAGENICS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | FDPS 2516/4885BTN3A1 3794/4885PDE3A 4276/4885 |
| US-20220275366-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SRRT, SNRPE | FDPS 1785/4885BTN3A1 3548/4885PDE3A 4040/4885 |
| US-20030143732-A1 | RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA | ADORA1, ADORA3, ADORA2A | FDPS 2859/4885BTN3A1 2018/4885PDE3A 2077/4885 |
| US-20030148507-A1 | RNA interference mediated inhibition of prostaglandin D2 receptor (PTGDR) and prostaglandin D2 synthetase (PTGDS) gene expression using short interfering RNA | PTGDR, PTGDR2, HPGDS | FDPS 403/4885BTN3A1 3358/4885PDE3A 1590/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | FDPS 2516/4885BTN3A1 3794/4885PDE3A 4276/4885 |
| US-20220056441-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (SINA) | AGO2, SNRPE, SRRT | FDPS 2516/4885BTN3A1 3794/4885PDE3A 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.